VTE in Pregnancy (DVT/PE + Thromboprophylaxis)
Clinical detail
Additional detail checked 2026-10-17 against the linked sources. This check covers the section below; the rest of the module retains its displayed verification status.
New unilateral leg symptoms, unexplained breathlessness, chest pain, haemoptysis or collapse in pregnancy or after birth require prompt assessment for thrombosis. Physiological pregnancy symptoms should not be used to dismiss a concerning presentation.
Assessment & interpretation
- For suspected DVT, compression ultrasound is central; persistent symptoms may justify repeat imaging after an initial negative scan.
- For suspected PE, the workup can include chest radiography, lung imaging and leg ultrasound, selected with the clinical team.
Decisions that change management
- Explain the benefits and risks of appropriate imaging. Avoiding necessary testing can leave a dangerous condition undiagnosed.
- Treatment and thromboprophylaxis use different dose pathways. The care plan must state the indication and account for renal function, weight and bleeding risk.
- Document a coordinated plan for anticoagulation around labour, procedures and neuraxial anaesthesia.
Follow-up & safety-netting
- Explain administration, bleeding precautions and symptoms requiring urgent help.
- Coordinate obstetric, medical and haematology follow-up and record the plan for treatment after birth and risk assessment in future pregnancies.
Clinical pitfalls
- This explanatory section does not replace a validated local pregnancy-PE diagnostic pathway or a patient-specific anticoagulant prescription.
Admission & discharge
Admission/discharge guidance checked 2026-10-18 against the linked sources. This is a clinical checklist for an individual decision, not an automatic discharge order.
When admission or continued hospital care is needed
- Suspected PE, haemodynamic or respiratory compromise, major bleeding risk, severe pain, extensive thrombosis or unsafe home treatment requires hospital care; unstable PE needs urgent critical-care treatment.
When clinic, day care or home care may be suitable
- Selected stable DVT/low-risk patients may be managed outside hospital only after specialist assessment, a safe anticoagulation plan and reliable follow-up/support.
Before going home
- The diagnosis/continuing investigation plan and anticoagulation indication are clear; oxygenation/haemodynamics and bleeding risk support the selected setting.
- The patient can self-inject or has assistance, has medicine supply, understands missed-dose/bleeding instructions and has a birth/neuraxial plan if still pregnant.
Discharge medicines and treatment changes
- Use therapeutic anticoagulation for diagnosed VTE, not the lower prophylaxis dose. RCOG treatment continues through pregnancy and for at least 6 weeks postpartum and at least 3 months in total.
- Reassess renal function, weight, bleeding risk and breastfeeding suitability; record exactly when to hold/restart around planned birth or procedures.
Medicine doses — use only when indicated
Use the medicines selected for this patient. Listed alternatives are not instructions to prescribe all of them together. Confirm the actual remaining course, pregnancy/postnatal context and monitoring plan.
Only the selected therapeutic regimen, adjusted to the individual patient; not routine prophylaxis.
- Indication: Confirmed or strongly suspected acute VTE in pregnancy unless anticoagulation is contraindicated
- Renal / hepatic: CrCl <30 mL/min: specialist regimen; consider IV unfractionated heparin when rapid reversal is needed
- Baseline CBC/platelets, renal/liver function and bleeding risk; clinical response
- Routine anti-Xa monitoring is not needed for most women; consider extremes of weight, renal impairment or recurrent VTE
- Stop therapeutic LMWH at least 24 h before planned neuraxial procedures; anaesthetic staff must prescribe postpartum restart using puncture time, catheter removal and haemostasis
Tests, pending results and their reviewer
- Assign review of any pending imaging, CBC/renal findings and drug monitoring required for the individual patient.
Home care and counselling
- Teach injection technique, sharps disposal, bleeding precautions, medicine interactions and the contact route for planned labour/procedures.
Follow-up: when and what to review
| When | Action / responsible service |
|---|---|
Before discharge | Name the anticoagulation/obstetric reviewer, provide a supply and book the next clinical review. |
Before stopping anticoagulation | Confirm the minimum course is complete and reassess continuing thrombosis risk; do not stop simply because leg symptoms improved. |
Return urgently
- Breathlessness, chest pain, haemoptysis, collapse, worsening unilateral leg symptoms or major bleeding requires immediate care.
Open the complete discharge checklist →
Treatment
① Immediate stabilization — first minutes
- Massive PE with collapse: resuscitate + consider systemic thrombolysis (alteplase 100 mg over 2 h) - obstetric teams should not fear it; deliver decision individualised
③ First-line treatment & drug regimens
- Confirmed or strongly suspected acute VTE in pregnancy unless anticoagulation is contraindicated
- Renal / hepatic: CrCl <30 mL/min: specialist regimen; consider IV unfractionated heparin when rapid reversal is needed
- Baseline CBC/platelets, renal/liver function and bleeding risk; clinical response
- Routine anti-Xa monitoring is not needed for most women; consider extremes of weight, renal impairment or recurrent VTE
- Stop therapeutic LMWH at least 24 h before planned neuraxial procedures; anaesthetic staff must prescribe postpartum restart using puncture time, catheter removal and haemostasis
- Risk-assessed obstetric thromboprophylaxis; standard-weight example, NOT VTE treatment
- Renal / hepatic: Reduced renal function requires a different dose/agent; do not reuse a standard prophylactic syringe without review
- Reassess VTE and bleeding risk after birth, surgery, admission or clinical change
- At least 12 h between prophylactic LMWH and neuraxial placement; postpartum restart needs an anaesthetic plan, adequate haemostasis and consideration of time since puncture/catheter removal
- Dalteparin/tinzaparin equivalents
- Warfarin POSTPARTUM only (teratogenic) when longer therapy needed; breastfeeding-compatible
④ Drug treatment detail (2 agents)
- Indication: Selected life-threatening PE, severe renal dysfunction or impending procedures when rapid reversibility is valuable
- Baseline CBC/platelets, coagulation and renal function; check APTT 6 h after starting and after dose changes
- Bleeding, Hb/platelets, HIT risk and procedure/neuraxial timing
- Indication: Expert-led reperfusion decision for haemodynamically unstable massive PE; pregnancy/postpartum bleeding risks require simultaneous obstetric/critical-care input
- Bleeding including genital/surgical/neuraxial sites, neurological status, BP, Hb and coagulation
- Pause/restart heparin according to APTT and the thrombolysis plan; arrange blood products and procedural alternatives
Definitive treatment
Anticoagulation is definitive therapy; duration per event type/risk.
Monitoring
| Domain | Rule |
|---|---|
Bleeding surveillance | PV loss quantified in labour plans |
Platelets | Baseline; periodic if extended course |
Renal function | CrCl <30 -> specialist dosing |
Neuraxial coordination | Anaesthetist-led timing chart at admission |
Response assessment
- Symptom resolution; no propagation on imaging where repeated
Treatment failure
- Recurrent VTE on LMWH -> check adherence/dose (anti-Xa), switch BD regimen, haematology input
Second-line treatment
- IV UFH peri-delivery windows where rapid reversal needed
Rescue treatment
Massive PE: alteplase; catheter-directed/embolectomy where available; protamine reversal for UFH emergencies.
Procedure / surgery
IVC filters rarely (contraindication to anticoagulation + recurrent PE).
Escalation
- ICU massive PE
- Haematology co-management complex cases
⑮ Complications & their management
Post-thrombotic syndrome
Compression stockings counselling
Anticoagulation near delivery
Planned induction timing lets last dose align with neuraxial windows
Post-treatment care
- >=6 weeks postpartum minimum (3 months total typical)
- Future-pregnancy prophylaxis plan documented
- Thrombophilia panel deferred/reconsidered
Diagnosis & assessment
- Haemodynamic instability suspected PE -> immediate thrombolysis decision
- Iliac DVT (whole-leg swelling + back pain)
- Post-CS breathlessness never dismissed as anaemia alone
- Anticoagulated + bleeding = dual emergency
Definition: DVT/PE antepartum or to 12 weeks postpartum.
Initial assessment
- DVT suspicion: whole-leg duplex compression US same day
- PE suspicion: CXR -> ECG -> ABG; CTPA or V/Q (both pregnancy-safe; CTPA first-line many units)
- Start LMWH BEFORE imaging if clinical probability high and no bleeding contraindication
- Baseline CBC (platelets!), renal function, weight documented
Investigations
| Test | Looking for |
|---|---|
Compression US leg | DVT confirmation |
CTPA/V-Q | PE confirmation |
D-dimer NOT useful in pregnancy | - |
Thrombophilia testing deferred 6+ wks post-treatment | Later workup only where management-changing |
Differential diagnosis
| Condition | Clue |
|---|---|
Normal pregnancy dyspnoea | Gradual, no hypoxia |
Pneumonia | Fever/focus |
Peripartum cardiomyopathy | Echo dysfunction |
AFE | Catastrophic intrapartum collapse |
Principles & follow-up
Management principles
Sources (9)
· checked 2026-10-17 · verified-live
Open source ↗
Scope: additional clinical-detail explanation for vte. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module.
· checked 2026-10-18 · verified-live
Open source ↗
Empiric anticoagulation pending objective exclusion, booking-weight LMWH, unfractionated-heparin 80 units/kg and 18 units/kg/hour with monitoring, life-threatening PE specialist reperfusion and treatment duration. 2015 edition. Additional admission/discharge check 18 October 2026 (limited to the fol…
· checked 2026-10-18 · verified-live
Open source ↗
Standard-weight prophylaxis table, duration based on risk, renal adjustment and neuraxial cautions. 2015 guideline, not represented as a new 2026 edition. Additional admission/discharge check 18 October 2026 (limited to the following): Repeat postpartum bleeding-versus-thrombosis risk assessment and…
· checked 2026-10-17 · verified-live
Open source ↗
Adult massive-PE 100 mg over 2 hours, reconstitution to 1 mg/mL, bleeding contraindications/monitoring and post-infusion heparin criteria. Not the stroke regimen or an automatic pregnancy recommendation.
· checked 2026-10-18 · verified-live
Open source ↗
Maternal/newborn transfer assessment, first void and effective feeding, handover, support/safeguarding, first midwife visit within 36 hours after transfer, postnatal danger symptoms. Full recommendations page read.
· checked 2026-10-18 · verified-live
Open source ↗
Normal-delivery discharge not less than 48 hours: full primary SOP PDF normal-delivery/discharge passages read. Corroborated by NHM CEmONC 2024 Part 1, chapter 8. This does not define a universal post-caesarean or complicated-case stay.
· checked 2026-10-18 · verified-live
Open source ↗
Official WHO summary read: at least 24-hour facility care after birth; additional contacts at 48–72 hours, 7–14 days and week 6; individual assessment/support. Summary facts only, not a claim that the full 242-page PDF was reviewed.
· checked 2026-10-18 · verified-live
Open source ↗
Full primary patient recovery page read: pain control, wounds, activity/VTE, urinary/bowel and infection warning signs, adult support and no driving/important decisions during the first 24 hours after general anaesthesia. Used as general recovery/handover principles, not operation-specific discharge…
· checked 2026-10-18 · verified-live
Open source ↗
Full primary recommendations read, focusing on critical-care-to-ward transfer: structured written handover, shared plan, monitoring, rehabilitation and receiving-team capability. Step-down is distinct from home discharge; no universal organ-support discharge cutoff is asserted.